Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Towards a PERsonalized MEdicine in Amyotrophic Lateral Sclerosis (ALS) by a Patient-tailored Genetic/Biomarker/iPSC Combined Approach - PERMEALS

NCT06917924 is registered in ClinicalTrials.gov with A.O.U. Città della Salute e della Scienza as lead sponsor.

NCT NCT06917924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Towards a PERsonalized MEdicine in Amyotrophic Lateral Sclerosis (ALS) by a Patient-tailored Genetic/Biomarker/iPSC Combined Approach - PERMEALS
Lead sponsor
A.O.U. Città della Salute e della Scienza
Phase
Observational
Overall status
Recruiting
Start date
May 20, 2023
Completion date
November 20, 2025
Enrollment
200 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)